Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 – Seasonal variation and association with outcome
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.115053 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Rebecca Schou Jurlander und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer Immunotherapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Denmark. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Seasons. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Danish Health Authority, Novo Nordisk Foundation.
Themen: Patientensicherheit
Abstract (Originalsprache)
INTRODUCTION: Immune checkpoint inhibitors (ICIs) carry the risk of immune-related adverse events (irAEs), a significant concern as therapy has transitioned to the adjuvant setting. Balancing therapeutic benefits against potential risks is crucial, necessitating real-world data from an unselected patient population in addition to clinical trial data to ensure optimal clinical decision-making. METHODS: This nationwide real-world study assessed irAEs in patients receiving adjuvant anti-PD1 therapy, primarily nivolumab, for resected stage III-IV melanoma between 2018-2022. Data were retrieved from two national databases: the IMMUNOTOX database and the Danish Metastatic Melanoma Database (DAMMED). IrAEs were sub-grouped according to organ systems graded using CTCAE ver. 5.0 ranging from mild toxicities (grade 1-2) to severe (grade 3-4) and fatal (grade 5). RESULTS: Among 792 included patients, (55 % male, median age 62 years (range 16-88)), 697 patients (88 %) experienced an irAE. Severe irAEs occurred in 116 patients (15 %) and five (0.6 %) died due to toxicity. A landmark analysis showed that patients who experienced at least one irAE before the 1st evaluation at 90 days had an increased progression free survival (PFS) (p = 0.032) and overall survival (OS) (p = 0.0071). Additionally, a seasonal pattern was noted with higher incidence of irAEs during summer. CONCLUSION: The prevalence of irAEs in real-world patients is comparable to the observed risk in clinical trials. Patients experiencing irAEs demonstrate a lower risk of melanoma relapse. Further, gender, age and seasonal variation may impact the incidence of irAEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Cancer Immunotherapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Denmark.
- Department of Oncology, Aarhus University Hospital, Denmark.
- Department of Oncology, Aalborg University Hospital, Denmark.
- Department of Oncology, Odense University Hospital, Denmark.
- Center for Cancer Immunotherapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Denmark. Electronic address: Inge.marie.svane@regionh.dk.
- Center for Cancer Immunotherapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Denmark. Electronic address: eva.ellebaek.steensgaard@regionh.dk.
Förderung
- Danish Health Authority
- Novo Nordisk Foundation
Zitieren
APA
Jurlander, R. S., Guldbrandt, L. M., Holmstroem, R. B., Madsen, K., Donia, M., Haslund, C. A., Schmidt, H., Bastholt, L., Ruhlmann, C. H., Svane, I. M., & Ellebaek, E. (2024). Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 – Seasonal variation and association with outcome. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.115053
Vancouver
Jurlander RS, Guldbrandt LM, Holmstroem RB, Madsen K, Donia M, Haslund CA, et al. Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 – Seasonal variation and association with outcome. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.115053
BibTeX
@article{Jurlander2024,
author = {Jurlander, Rebecca Schou and Guldbrandt, Louise Mahncke and Holmstroem, Rikke B and Madsen, Kasper and Donia, Marco and Haslund, Charlotte A and Schmidt, Henrik and Bastholt, Lars and Ruhlmann, Christina H and Svane, Inge Marie and Ellebaek, Eva},
title = {Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 – Seasonal variation and association with outcome},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.115053}
}
EUVIMED